Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg in Overweight and Obesity
NCT06041217Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Semaglutide 2.4 milligram (mg) with Placebo (2 arms). Primary endpoints: Change in Body Weight (%) at 44 weeks and Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (>=) 5% at 44 weeks. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06041217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041217.